Overview

Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of Oral ASN51 in Healthy Subjects and Subjects With Alzheimer's Disease

Status:
Recruiting

Trial end date:
2022-01-31

Target enrollment:

Participant gender:

Summary

ASN51-101 is a randomized, double-blind, placebo-controlled, phase 1 first in human (FIH) safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) study of oral ASN51 in healthy young adult and elderly subjects and elderly subjects with AD. The study is comprised of three parts (Part 1, Part 2, and Part 3).

Phase:

Phase 1

Details

Lead Sponsor:

Asceneuron Pty Ltd.
Asceneuron S.A.

Collaborators:

Asceneuron Pty Ltd.
Asceneuron S.A.
Neuroscience Trials Australia